Taiwan Biomaterial Co., Ltd. engages in the development and sale of implantable medical devices in Taiwan. It provides Foamagen, a foamagen dura substitute; stroke thrombus negative pressure removal catheter system comprising suction and removal of cerebrovascular embolism blood clot for the pump system, and nickel-titanium guidewire for guiding cerebral vascular surgery; tissue repair and regeneration products for the treatment of early osteoarthritis; and CDMO. The company was founded in 1921 and is based in Zhubei, Taiwan.
Frequently asked questions
What sector does Taiwan Biomaterial Co., Ltd. (6649) operate in?
Taiwan Biomaterial Co., Ltd. belongs to the Other sector and operates in the Medical Devices industry.
What is Taiwan Biomaterial Co., Ltd. (6649) current stock price?
As of the latest data, Taiwan Biomaterial Co., Ltd. stock price is NT$35.15, with a previous close of NT$35.15.
What is Taiwan Biomaterial Co., Ltd. (6649) current market capitalization?
Taiwan Biomaterial Co., Ltd. market cap is approximately 1.48 billion.
What is Taiwan Biomaterial Co., Ltd. (6649) Earnings Per Share (EPS)?
The trailing EPS is NT$0.61.
What is Taiwan Biomaterial Co., Ltd. (6649) Price-to-Earnings (P/E) ratio?
Taiwan Biomaterial Co., Ltd. current P/E ratio is 57.62.
Does Taiwan Biomaterial Co., Ltd. (6649) pay dividends?
Yes. Taiwan Biomaterial Co., Ltd. pays annual dividends with an annualized yield of 2.84% and an estimated annual payout of NT$1.00 per share.
When is the next ex-dividend date for Taiwan Biomaterial Co., Ltd. (6649)?
The next ex-dividend date is scheduled for April 09, 2027.
What is Taiwan Biomaterial Co., Ltd. (6649) beta (volatility) score?
Taiwan Biomaterial Co., Ltd. has a beta of 0.383, indicating lower volatility than the overall market.
